AstraZeneca and Daiichi Sankyo partner with Summit Therapeutics on Phase III triple‑negative breast cancer trial
AstraZeneca, Daiichi Sankyo and Summit Therapeutics announced a clinical collaboration to evaluate the combination of Datroway and ivonescimab in a Phase III study for first‑line triple‑negative breast cancer. AstraZeneca recently invested $2 billion in Summit, acquiring an estimated 12% equity stake. Each partner will supply its own drug, share trial costs and retain development and commercial rights.
Why it matters
The $2 billion equity injection provides funding for the joint trial and gives AstraZeneca a sizable ownership position in Summit, aligning the companies' financial interests. The Phase III study could broaden the approved uses of both Datroway and ivonescimab, potentially adding a new breast‑cancer indication to Summit’s pipeline.
Key facts
- 1AstraZeneca invested $2 billion in Summit Therapeutics. benzinga.com
- 2The investment gave AstraZeneca an estimated 12% stake in Summit. finance.yahoo.com
- 3The partners will conduct a Phase III trial of Datroway with ivonescimab in first‑line triple‑negative breast cancer. benzinga.com
- 4Datroway is a TROP2‑directed DXd antibody‑drug conjugate co‑developed by Daiichi Sankyo and AstraZeneca. benzinga.com
- 5Ivonescimab is a bispecific PD‑1/VEGF antibody approved in China for a subset of non‑small cell lung cancer patients. benzinga.com
- 6AstraZeneca shares were up 0.59% at $158.63 in pre‑market trading. benzinga.com
Summary written by AlphAI from 8 of 8 sources. Not investment advice. Figures are as stated by the linked sources.